Press Releases Zai Lab Limited Hong Kong S.E.

Equities

9688

KYG9887T1168

Market Closed - Hong Kong S.E. Other stock markets 01:38:35 22/05/2024 pm IST			5-day change	1st Jan Change
15.68 ^HKD	-1.13%		-2.73%	-27.07%

20/05	Chinese Regulator Approves Zai Lab’s New Drug Application for Bacterial Pneumonia Drug	MT
20/05	Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis	05:01pm	BU
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	21/05	AQ
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	20/05	BU
Zai Lab Announces Participation in May and June Investor Conferences	16/05	BU
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China	14/05	BU
Zai Lab Announces Approval of AUGTYRO for Patients with ROS1-positive NSCLC by China's NMPA	13/05	AQ
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA	13/05	BU
Zai Lab : Corporate Presentation	09/05	PU
Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates	09/05	BU
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024	15/04	BU
Zai Lab Statement on Executive Management Team's Agreement on Share Activities	12/04	AQ
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities	11/04	BU
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI Meets Primary Endpoint	02/04	AQ
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs	02/04	BU
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...	01/04	BU
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases	28/03	AQ
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer	27/03	BU
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors	14/03	BU
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)	07/03	BU
Zai Lab Announces Participation in March Investor Conference	06/03	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Zai Lab Limited Hong Kong S.E.

Equities

9688

KYG9887T1168

Press Releases

Filters